ITF Therapeutics LLC’s Post

Another insanely amazing story to share. When I sat down with Elliot he put all his cards on the table. He’s a young and ambitious System Clinical Manager who’s passionate patient safety and making a difference every in the field of pharmacy! Check out his story in celebration of #pharmacyweek

Incredible results in a challenging study proves #Dermtech can accurately rule out melanoma greater than 99% of the time. Trust II is a follow up study on an already successful trial; which is rarely done. The reason being that the possibility of contradicting your initial positive results is a risk very few companies are willing to take. #Dermtech enrolled 8,000 more patients than Trust I to validate its claims as a first in class melanoma rule out test. The outcome provides concordance to TRUST 1 that the NPV for this test is still greater than 99%

Clinical trial treatments at UW Health | Carbone Cancer Center have given Gary Davey more time to create new memories with his family. About 14 years after he was first diagnosed with prostate cancer, Gary now has no evidence of disease and leads an active lifestyle. Check out this video to hear more about Gary's treatments: https://lnkd.in/gdSz8EdR #prostatecancer #clinicaltrials #cancerresearch

"In Gary's situation, he was one of the first 20 patients who was enrolled and treated with this [#drug] combination. And it's because of Gary's participation in that trial that we figured out that not only is this effective, it can be effective for years and years of time. And now it's FDA approved across the world." - Dr. Joshua Lang, UW Carbone Cancer Center "They gave me an opportunity to live, and we've created a drug that's going to give those people with the same condition as me an option." - Gary Davey View the video below to learn more about Mr. Davey's inspiring journey. #cancer #clinicaltrials #clinicalresearch #university #Wisconsin #FDA

WATCH: Experts discuss several recent data updates in polycythemia vera and myelofibrosis in the context of the treatment landscape and its impact on clinical practice. #oncology https://lnkd.in/e3eHM6K7

OnCusp Therapeutics, Inc. has queued a Phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6)-directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors. CUSP06 is composed of a proprietary antibody with high CDH6 binding affinity, a protease cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The study has an estimated enrollment of 180 patients and start date in Feb 2024. #mabs https://lnkd.in/eH56GPSE

Clinical trials can be used to study a variety of different cancer drugs and medical treatments, and real-world evidence can play an important role in supporting these trials. Watch this video blog featuring Dr. Nicholas Robert and Dr. Paul Conkling to learn more. #Oncology #ClinicalTrials #Healthcare #RWE

The process of finding and participating in a clinical trial can be crazy hard, as Bess Bess Stillman, M.D. and Jake Seliger capture so well in each of their descriptions of Jake's experience with head and neck cancer. Making this process easier is obviously a win-win-win (patients-investigators-sponsors). What can we do, as an industry, to make this happen? In the very-near term, for starters, I hope we'll see more sponsors revising traditional inclusion criteria to make studies more inclusive, facilitating easier access (e.g., childcare, transportation, flexible clinic hours) and gathering more patient input on trial designs. 84% of large Pharma companies currently have a public policy commitment to increase diversity in clinical trials. When it's this hard for a white guy to find and enroll in the study of his choice, expanding diversity is clearly a heavy lift. This is an all-hands-on-deck call to action for the clinical research ecosystem.